Schrödinger
schrodinger.com
Physics-based software for drug discovery.
Quick Information
- Category:
- Healthcare
- Pricing:
- Contact Sales
- Platforms:
- Desktop, Cloud, Web
- Free Plan:
- No
- Last Verified:
- October 2026
What Is Schrödinger?
Schrödinger sells physics-based computational software used to discover and design molecules, mainly for drug discovery. It is a public company on Nasdaq as SDGR, and it earns money in two ways: software subscriptions sold to pharma, biotech and materials customers, and a drug discovery business that collects milestone payments from its own collaborations. The company has also introduced Bunsen, an AI co-scientist for molecular discovery.
Its 2026 numbers show a company in transition. Second quarter revenue was about $58.9 million, up around 8% year on year, with software revenue of $32.5 million, down 10%, and drug discovery revenue up 65% to $23.0 million on milestones. Hosted deployments reached 47% of software revenue, and management is moving customers to hosted subscription contracts, which changes reported revenue timing and margins without affecting annual contract value or cash. Software gross margin was 71%, down from 76%. The company guided full-year 2026 ACV to $218 million to $228 million, 10% to 15% growth, and 2025 total revenue was $256 million, including $200 million from software. The search did not break out revenue by individual product.
Schrödinger suits computational chemists and pharma R&D teams that want physics-based simulation alongside machine learning. Compare Insilico Medicine, Recursion and Isomorphic Labs. Browse the Healthcare tools directory for more.
What Can You Use Schrödinger For?
Molecular modelling
Simulate how molecules interact.
Drug design
Design and optimize drug candidates.
Materials science
Apply the platform beyond pharma.
Schrödinger Features
- Physics-based simulation — Core of the software platform.
- Bunsen AI co-scientist — Introduced for molecular discovery.
- Hosted deployment — 47% of software revenue in Q2 2026.
- Public reporting — Quarterly results as SDGR.
Who Is Schrödinger For?
- Pharma and biotech R&D teams — Use simulation to prioritize compounds.
- Materials scientists — Model molecules and materials.
Schrödinger Pros & Limitations
What We Like
- Established physics-based approach
- Transparent public financials
- Guided ACV growth of 10% to 15% for 2026
Limitations
- Software revenue fell in Q2 2026
- Pricing is not public
- Product-level data was not available in the sources
Schrödinger Pricing
| Plan | Price | Main Features |
|---|---|---|
| Software subscription | Custom, annual contracts | Physics-based molecular modelling software, hosted or on-premise |
| Drug discovery collaborations | Milestone-based | Partnered programs |
Pricing was last verified October 2026. Check the official website for the latest pricing.
AI Listing Jungle Ranking
- Global Rank:
- #870
- Overall Score:
- 48.1/100
- Monthly Users:
- –
- Rank Change:
- ▼ 222
This ranking reflects AI Listing Jungle's own independent scoring methodology and is not an endorsement by Schrödinger or its company. How Our Rankings Work
Frequently Asked Questions
What does Schrödinger sell?
Physics-based computational software for drug and materials discovery.
Is it public?
Yes, on Nasdaq as SDGR.
What did Q2 2026 look like?
Revenue of about $58.9M, up 8%, with software revenue of $32.5M, down 10%.
What is Bunsen?
An AI co-scientist for molecular discovery introduced by the company.
Our Take
Schrödinger is a long-standing leader in simulation, now layering AI on top.
Reported software revenue is shifting because of hosted contracts, so look at ACV too.
Schrödinger Alternatives
Schrödinger Comparisons
Ready to try Schrödinger?
Visit the official website to get started.
Visit Official WebsiteAI Listing Jungle is an independent AI tools directory. Product names, logos, and trademarks belong to their respective owners.